Zealand Pharma (ZEAL) to Unveil Petrelintide Phase 3 Data at ADA 2026

[Para 1: The Lead] Zealand Pharma A/S (NASDAQ: ZEAL) will present complete results from the pivotal Phase 3 ZUPREME-1 trial of its amylin analog petrelintide at the American Diabetes Association’s 86th Scientific Sessions (ADA 2026) in Orlando, Florida, the company announced on May 27, 2026. [Para 2-3: Supporting details & Context] The late-breaking data, submitted for oral presentation, could position petrelintide as a potential competitor in the metabolic disease space. ZUPREME-1 evaluated the therapy’s efficacy on weight loss and glycemic control in adults with obesity or overweight with type 2 diabetes. Zealand previously stated the trial met its co-primary endpoints in top-line data released in early 2026, but has withheld specific figures until this major medical conference. Investors will scrutinize the magnitude of weight reduction and tolerability against established incretin-based therapies. Shares of Zealand rose 4.2% in early Copenhagen trading following the disclosure.